Back to top
more

Regulus Therapeutics (RGLS)

(Delayed Data from NSDQ)

$2.00 USD

2.00
263,459

0.00 (0.00%)

Updated May 17, 2024 04:00 PM ET

After-Market: $2.00 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for RGLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

4 items in cart

View Cart/Checkout

Regulus Therapeutics Inc. [RGLS]

Reports for Purchase

Showing records 201 - 220 ( 270 total )

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 201

02/09/2015

Company Report

Pages: 6

Raising PT on Spectacular 4mg/kg Single Dose Results, in Our View; Reiterate OUTPERFORM and Raising PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 202

02/09/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 203

02/03/2015

Daily Note

Pages: 42

February and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 204

01/11/2015

Daily Note

Pages: 5

2015 Clinical Map Initiative Suggests Aggressive Pipeline Progress and Multiple Value-Drivers; Reiterate OUTPERFORM and $23 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 205

01/11/2015

Daily Note

Pages: 5

2015 Clinical Map Initiative Suggests Aggressive Pipeline Progress and Multiple Value-Drivers

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 206

01/09/2015

Company Report

Pages: 10

Raising Price Target

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 207

01/02/2015

Industry Report

Pages: 46

January and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 208

11/18/2014

Daily Note

Pages: 5

ASN Review: RG-012 Demonstrates Robust Efficacy in Preclinical Studies for Alport Syndrome; Reiterate OUTPERFORM and $23 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 209

11/18/2014

Daily Note

Pages: 5

ASN Review: RG-012 Demonstrates Robust Efficacy in Preclinical Studies for Alport Syndrome

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 210

11/07/2014

Company Report

Pages: 6

Q3 Financials and Pipeline Update; Anticipate Multiple Catalysts in 2015; Reiterate OUTPERFORM and $23 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 211

11/04/2014

Daily Note

Pages: 46

November and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 212

10/29/2014

Company Report

Pages: 7

Financing Provides Flexibility for Pipeline Development & Runway Well Into 2016; Reiterate OUTPERFORM and Increasing PT to $23 for HCV Upside.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 213

10/24/2014

Daily Note

Pages: 5

ASN Preview: Preclinical Data Suggest RG012 Could Be a Transformative Treatment for Alport Syndrome; Reiterate OUTPERFORM and $19 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 214

10/22/2014

Daily Note

Pages: 5

RG-101 Treatment of HCV Shows Potent and Broad Initial Efficacy

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 215

10/14/2014

Daily Note

Pages: 5

Preclinical Data at OTS Also Supports Potentially Material Clinical Catalyst in Q4; Reiterate OUTPERFORM and $19 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 216

10/12/2014

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 217

10/01/2014

Daily Note

Pages: 46

October and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 218

09/18/2014

Daily Note

Pages: 5

Initiation of Alport Natural History Study; First Clinical Catalyst Expected in Q4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 219

09/12/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 220

08/26/2014

Daily Note

Pages: 46

September and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party